Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the role of rash in the treatment of cancer with agents targeting the epidermal growth factor receptor
- Identify strategies to prevent or reduce chemotherapy-induced nausea and vomiting
- Discuss the role of inflammation in symptom complexes in cancer patients
- Explain current changes in the use of erythropoiesis-stimulating agents in the setting of cancer therapy
Topics covered include:
-
Adverse Skin Reactions Associated With Targeted Therapy
-
Use of Casopitant for Prevention of Nausea and Vomiting in Moderately and Highly Emetogenic Chemotherapy
-
Cytokine-Associated Proinflammatory Symptoms
-
Effect of Reduced Use of Erythropoiesis-Stimulating Agents on Transfusion Resources
-
Alcoholism Screening in Patients With Advanced Cancer